Novavax (NASDAQ: NVAX) reported Q1 EPS of $2.56, $0.13 worse than the analyst estimate of $2.69. Revenue for the quarter came in at $704 million versus the consensus estimate of $845.2 million.

GUIDANCE:

Novavax sees FY2022 revenue of $4-5 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.